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Abstract
Although much evidence has been accumulated suggesting that tumor necrosis factor-K (TNF-K) is an important mediator
of insulin resistance, the precise mechanism involved is still unclear. Recently, it has been reported that insulin-induced
glucose uptake is mediated by activation of second messengers such as insulin receptor substrate 1 (IRS-1),
phosphatidylinositol 3-kinase (PI3K), and diacylglycerol (DG)-protein kinase C (PKC). We have examined the effect of
TNF-K on insulin-induced glucose uptake and activations of tyrosine kinase, IRS-1, PI3K and PKC in rat adipocytes.
Pretreatment with 0.1^100 nM TNF-K for 60 min resulted in a significant decrease in 10 nM insulin- or 1 WM 12-O-
tetradecanoyl phorbol-13-acetate (TPA)-induced [3H]2-deoxyglucose uptake without affecting basal glucose uptake. 10 nM
insulin-stimulated activation of tyrosine kinase, IRS-1 and PI3K was suppressed by preincubation with 0.1^10 nM TNF-K
for 60 min. 10 nM TNF-K pretreatment also suppressed 10 nM insulin- and 1 WM TPA-induced increases in membrane-
associated PKCL and PKCj. Furthermore, 10 nM TNF-K, by itself, altered PKCL translocation from the membrane to
cytosol. These results suggest that TNF-K inhibits insulin-stimulated activation of both the tyrosine kinase-IRS-1-PI3K-
PKCj pathway and DG-PKC pathway. Finally, TNF-K contributes to insulin resistance in rat adipocytes. ß 1999 Elsevier
Science B.V. All rights reserved.
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1. Introduction
In previous studies, activation of protein kinase C
(PKC) has been demonstrated to be an important
mechanism for transduction of signals generated
upon external stimulation of cells by hormones, neu-
rotransmitters and growth factors [1]. In particular,
several investigations suggest that PKCL, a conven-
tional PKC member which is the abundant PKC iso-
form among various PKC isoforms in rat adipocyte
[2^4], is translocated from the cytosol to membrane
in response to treatment of rat insulin-sensitive tissue
[5^7] with insulin and/or TPA. We previously re-
ported that insulin-induced glucose uptake is associ-
ated with PKC activation in insulin-sensitive tissue
[2,3,7,8], and insulin stimulation of glucose uptake is
inhibited by PKC inhibitors [9,10].
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On the other hand, tumor necrosis factor-K (TNF-
K) is a cytokine with a variety of biological functions,
including insulin resistance [11^14]. Recently, two
major hypotheses regarding TNF-K-induced insulin
resistance have been raised. First, treatment of insu-
lin-sensitive cells with TNF-K may downregulate glu-
cose transporter 4 (GLUT4) mRNA levels in cul-
tured cells and rat adipocytes [11,15^17]. Second,
treatment of insulin-sensitive cells with TNF-K has
been suggested to lead to serine phosphorylation of
IRS-1 and to converting it into an inhibitor of tyro-
sine kinase of an insulin receptor (IR) L-subunit
[18,19].
However, insulin resistance in rat adipocytes medi-
ated by TNF-K has not yet been fully elucidated. The
purpose of this study is to determine whether treat-
ment of rat adipocytes with TNF-K can alter PKC
activation and a¡ect insulin signal transduction. We
report here that (1) TNF-K suppresses insulin- and
TPA-induced [3H]2-deoxyglucose uptake; (2) TNF-K
decreases tyrosine kinase activity, tyrosine phospho-
rylation of IRS-1, and PI3K activity; and (3) TNF-K
suppresses activation of membrane-associated PKCL
and j in rat adipocytes.
In conclusion, this study provides novel informa-
tion that TNF-K modulates insulin- and TPA-stimu-
lated glucose uptake and alters the distribution of
PKCL and j in addition to inhibiting tyrosine kin-
ase-IRS-1-PI3K signaling.
2. Materials and methods
2.1. Materials
Human insulin was obtained from Novo-Nordisk
(Copenhagen, Denmark). [Q-32P]ATP and [125I]insu-
lin were purchased from Amersham (Buckingham-
shire, UK). [1,2-3H]2-deoxyglucose ([3H]2-DOG)
was purchased from DuPont-NEN (Boston, MA).
Recombinant murine TNF-K was purchased from
Sigma (St. Louis, MO). C2-ceramide was purchased
from BIOMOL (Plymouth Meeting, PA). All other
chemicals were of reagent grade.
2.2. Antibodies
Anti-phosphotyrosine (PY) antibody was pur-
chased from Transduction Laboratory (Lexington,
KY). Anti-IRS-1 (carboxy-terminal, polyclonal IgG)
and anti-IR L-subunit (human, polyclonal IgG) anti-
bodies were purchased from Upstate Biotechnology
(Lake Placid, NY). Anti-PKCL and j antibodies
were purchased from Gibco BRL Products (Gai-
thersburg, MD).
2.3. Adipocyte experiments
Male Wistar rats weighing 150^200 g were fed ad
libitum and killed by decapitation. Isolated adipo-
cytes were obtained by collagenase digestion of rat
epididymal fat pads in Krebs-Ringer phosphate
(KRP) bu¡er (pH 7.4) containing 127 mM NaCl,
12.3 mM NaH2PO4, 5.1 mM KCl, 1.3 mM MgSO4,
1.4 mM CaCl2, 3% bovine serum albumin (BSA) and
2.5 mM glucose [20]. Adipocytes were washed and
incubated at 37‡C in glucose-free KRP bu¡er con-
taining 1% BSA for 30 min.
2.4. Glucose uptake study
First, isolated rat adipocytes were incubated with
or without 0.1^100 nM TNF-K for 60 min, followed
by treatment with 10 nM insulin or 1 WM TPA for
30 min. Uptake of [3H]2-DOG was measured over
1 min after treatment with 10 nM insulin or 1 WM
TPA as described previously [21]. Second, isolated
rat adipocytes were treated with TNF-K alone
(0.01^10 nM) or C2-ceramide alone (0.1^30 WM)
for 60 min. Uptake of [3H]2-DOG was measured
over 1 min after treatment with TNF-K or C2-ceram-
ide for 60 min. Third, isolated rat adipocytes were
incubated with or without 1^30 WM C2-ceramide for
60 min, followed by treatment with 10 nM insulin or
1 WM TPA for 30 min. Uptake of [3H]2-DOG was
measured over 1 min after treatment with 10 nM
insulin or 1 WM TPA for 30 min.
2.5. Insulin binding study
Isolated rat adipocytes were incubated with or
without 10 nM TNF-K for 60 min, and then incu-
bated with [125I]insulin and unlabeled insulin in plas-
tic tubes at 25‡C in a shaking water bath for 60 min
as described previously [22]. Incubation was termi-
nated by removing 300 Wl aliquots from the cell sus-
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pension, and the cells were rapidly centrifuged in
plastic microfuge tubes to which 100 Wl silicone oil
had been added. The cells were then removed, and
the radioactivity was determined. All studies were
performed in triplicate.
2.6. Immunoprecipitation and Western blot analysis
Adipocytes were preincubated with or without
0.1^10 nM TNF-K for 60 min. The samples were
treated with 10 nM insulin for 10 min, and were
terminated by the addition of ice-cold bu¡er A
(20 mM Tris-HCl, pH 7.5, 140 mM NaCl, 20 WM
phenylmethylsulfonyl £uoride (PMSF), 1% Triton
X-100, 1 mM ethylene glycol bis (L-aminoethyl-
ether)-N,N,NP,NP-tetraacetic acid (EGTA), 0.5 mM
Na3VO4, 10% glycerol, 1 mM dithiothreitol (DTT),
and 10 Wg/ml aprotinin). The obtained samples were
immediately homogenized in bu¡er A, then the ho-
mogenates were centrifuged at 1000Ug for 2 min,
and any £oating fatty material was removed. Pro-
tein concentration of the resultant homogenates was
determined. 5 Wg of anti-IR L-subunit antibody or
anti-IRS-1 antibody was added to 500 Wg of protein
and incubated at 4‡C overnight. 30 Wl of protein A
agarose (Sigma, St. Louis, MO) was added and in-
cubation was performed for 2 h at 4‡C. The sam-
ples were microcentrifuged, and the pellet was
washed twice with washing bu¡er B (20 mM Tris-
HCl, pH 7.5, 140 mM NaCl, 1 mM DTT and 1%
Nonidet P-40) and twice with washing bu¡er C
(10 mM Tris-HCl, pH 7.5, 100 mM NaCl and
1 mM DTT). The pellet was resuspended in 50 Wl
of Laemmli sample bu¡er and boiled for 2 min at
100‡C. After the supernatants were removed, 25 Wl
of each sample was subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), and transferred to a nitrocellulose mem-
brane (NC). The NC was incubated with anti-PY
antibody, and subjected to an ECL (enhanced
chemiluminescence) Western blotting detection sys-
tem (Amersham, Buckinghamshire, UK) according
to the manufacturer’s protocol. These results were
scanned and analyzed with a laser densitometer
(UltroScan XL, Pharmacia LKB Biotechnology,
Tokyo).
2.7. PI 3-kinase activity
Isolated rat adipocytes were preincubated with or
without 0.1^10 nM TNF-K for 60 min. The samples
were treated with 10 nM insulin, and were lysed im-
mediately in lysis bu¡er (20 mM Tris-HCl, pH 7.5,
140 mM NaCl, 20 WM PMSF, 0.5 mM Na3VO4,
1 mM EGTA, 10% glycerol and 1% Nonidet P-40).
The lysates were centrifuged at 15 000Ug for 10 min
at 4‡C. 5 Wg of anti-PY antibody was added to 500 Wg
of the above resultant supernatant and incubated at
4‡C overnight. After addition of protein A agarose
for 2 h, the immunoprecipitates were washed twice
with bu¡er B, once with LiCl solution (100 mM Tris-
HCl, pH 7.5, 0.5 M LiCl and 1 mM DTT), and twice
with bu¡er C. The PI3K reaction was started by
addition of a 40 Wl solution containing 20 mM
Tris-HCl, pH 7.4, 10 WCi [Q-32P]ATP, 250 WM
ATP, 10 mM MgCl2, 5 mM EGTA and 20 Wl
(1 mg/ml) of sonicated phosphatidylinositol. After a
10 min incubation at 30‡C, the reaction was termi-
nated by the addition of 500 Wl 1 N HCl. Then, in
succession, 500 Wl of CHCl3/methanol (2:1, v/v) was
added to the samples which were then centrifuged.
The extracts were washed with 500 Wl of CHCl3/
methanol/1 N HCl (4:2:3, v/v), then dried and resus-
pended in CHCl3. The samples were spotted onto
Silica gel 60 thin-layer chromatography (TLC) plates
(Merck, Darmstadt, Germany), and visualized by
autoradiography (X-OMAT ¢lm, Eastman Kodak,
Rochester, NY). These results were scanned and an-
alyzed with a laser densitometer.
2.8. PKC studies
First, the samples were treated with 10 nM insulin
or 1 WM TPA for 10 and 20 min, respectively, fol-
lowing preincubation with 10 nM TNF-K for 60 min,
and were terminated by the addition of ice-cold
bu¡er D (20 mM Tris-HCl, pH 7.5, 0.25 M sucrose,
1.2 mM EGTA, 0.1 mM PMSF, 20 Wg/ml leupeptin,
20 mM 2-mercaptoethanol and 10 Wg/ml aprotinin).
Second, isolated rat adipocytes were treated with
10 nM TNF-K alone for 10 min and 30 min, respec-
tively. Reactions were terminated by the addition of
ice-cold bu¡er D. Each sample was sonicated in
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bu¡er D. The homogenates were centrifuged for
60 min at 105 000Ug to separate the cytosol and
membrane fractions. After the membranes were re-
suspended in lysis bu¡er (20 mM Tris-HCl, pH 7.5,
0.25 M sucrose, 20 Wg/ml leupeptin, 20 mM 2-mer-
captoethanol, 5 mM EGTA, 0.1 mM PMSF, 2 mM
ethylenediaminetetraacetic acid and 1% Triton X-
100) for 30 min at 4‡C, they were sonicated, and
then centrifuged for 60 min at 105 000Ug to obtain
solubilized membrane fractions. They were then re-
suspended in Laemmli sample bu¡er and boiled for
2 min at 100‡C. 50 Wg of each sample was subjected
to SDS-PAGE, transferred to NC, and subjected to
Western analysis with anti-PKCL or j antibody as
described above. These results were scanned and an-
alyzed with a laser densitometer.
2.9. Statistical analysis
The data are presented as standard error of the
means (S.E.M.) unless otherwise stated, and statisti-
cal signi¢cance was determined by a Student’s t-test
or Fisher’s protected least signi¢cant di¡erence
(Fisher’s PLSD) test.
3. Results
3.1. E¡ect of TNF-K pretreatment on insulin- or
TPA-induced [3H]2-DOG uptake and
[125I]insulin-speci¢c binding to rat adipocytes
First, in the absence of any prior treatment with
TNF-K, 10 nM insulin stimulation for 30 min pro-
voked an approximately 7-fold increase in [3H]2-
DOG uptake (688 þ 33%), and 1 WM TPA stimula-
tion for 30 min provoked 3^4-fold increases
(343 þ 33%), when compared with the control
(100%) (Fig. 1A). Pretreatment with 0.1, 1, 10 and
100 nM TNF-K for 60 min diminished 10 nM insu-
lin-stimulated [3H]2-DOG uptake to 5.6-, 5.5-, 4.1-
and 3.9-fold increases over the control (100%), re-
spectively (Fig. 1A). Similarly, 1 WM TPA-stimulated
[3H]2-DOG uptake after 0.1, 1, 10 and 100 nM TNF-
K pretreatment for 60 min was reduced to 2.8-, 2.6-,
2.3- and 1.8-fold increases over the control (100%),
respectively (Fig. 1A). These results demonstrate that
10 nM TNF-K pretreatment for 60 min was su⁄cient
to suppress both 10 nM insulin- and 1 WM TPA-
induced glucose uptake (the double asterisks in Fig.
Fig. 1. (A) E¡ect of TNF-K pretreatment on insulin- or TPA-induced [3H]2-DOG uptake. Rat adipocytes were incubated with or
without 0.1^100 nM TNF-K for 60 min, followed by treatment with 10 nM insulin or 1 WM TPA for 30 min. Control values are indi-
cated as 100%. Insulin- or TPA-induced percent change (with or without TNF-K pretreatment) was expressed as the mean þ S.E.M.
*P6 0.05 or **P6 0.01 vs. insulin-stimulated (without TNF-K pretreatment) value. #P6 0.05 or ##P6 0.01 vs. TPA-stimulated (with-
out TNF-K pretreatment) value. P was determined by Fisher’s PLSD test. The results are an average of 3^6 determinations and repre-
sentative for two di¡erent experiments. (B) E¡ect of TNF-K pretreatment on [125I]insulin-speci¢c binding. Rat adipocytes were incu-
bated with (b) or without (a) 10 nM TNF-K for 60 min, followed by treatment with [125I]insulin and unlabeled insulin at 25‡C for 60
min. Binding activity was measured as shown in Section 2. 10 nM TNF-K pretreatment had no in£uence on insulin binding. These
studies are expressed as the mean þ S.E.M. of triplicate determinations from two di¡erent experiments. P was determined by a
Student’s t-test.
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1A indicate P6 0.01 (Fisher’s PLSD test) in rat adi-
pocyte).
Second, we examined the e¡ect of 10 nM TNF-K
on [125I]insulin speci¢c binding to adipocytes. 10 nM
TNF-K pretreatment had no in£uence on insulin
binding (Fig. 1B). This result indicated that the e¡ect
of TNF-K on insulin resistance may have been im-
paired during post receptor signaling.
3.2. TNF-K- or C2-ceramide-induced [3H]2-DOG
uptake and e¡ect of C2-ceramide pretreatment on
insulin- or TPA-induced [3H]2-DOG uptake
First, we examined TNF-K alone- and ceramide
(C2-ceramide) alone-induced [3H]2-DOG uptake in
rat adipocytes. Ceramide is con¢rmed as one of the
mediators which are induced by cytokines, including
TNF-K. Recently, Brindley et al. stated that in the
absence of insulin, C2- and C6-ceramides increased
[3H]2-DOG uptake in 3T3-L1 adipocytes [23]. How-
ever, TNF-K (0.01^10 nM) and C2-ceramide (1^
30 WM) treatment for 60 min had no signi¢cant in-
£uence on [3H]2-DOG uptake in this system, when
compared with the control (without TNF-K or
C2-ceramide treatment; 100%) (Fig. 2A).
Second, we also examined the e¡ect of C2-ceram-
ide pretreatment for 60 min on insulin- or TPA-in-
duced [3H]2-DOG uptake. In the absence of any pri-
or treatment with C2-ceramide, 10 nM insulin
stimulation for 30 min provoked an approximately
6
Fig. 2. (A) TNF-K alone- or C2-ceramide alone-induced [3H]2-
DOG uptake. Isolated rat adipocytes were treated with only
TNF-K (0.01^10 nM) or only C2-ceramide (0.1^30 WM) for
60 min. Uptake of [3H]2-DOG was measured over 1 min after
treatment with TNF-K or C2-ceramide for 60 min. 0.01^10 nM
TNF-K-induced [3H]2-DOG uptake exhibited no signi¢cant
change, when compared with the control (without TNF-K treat-
ment; 100%) (upper panel). 0.1^30 WM C2-ceramide-induced
[3H]2-DOG uptake exhibited no signi¢cant change, when com-
pared with the control (without C2-ceramide treatment; 100%)
(lower panel). The results are an average of 3^6 determinations
from three di¡erent experiments. These studies are expressed as
the mean þ S.E.M. (Fisher’s PLSD test). (B) E¡ect of C2-ceram-
ide on insulin- and TPA-induced [3H]2-DOG uptake. Isolated
rat adipocytes were pretreated with or without 1^30 WM C2-ce-
ramide for 60 min, followed by treatment with 10 nM insulin
or 1 WM TPA for 30 min. Uptake of [3H]2-DOG was measured
over 1 min after treatment with 10 nM insulin or 1 WM TPA
for 30 min. Pretreatment with 10 and 30 WM C2-ceramide for
60 min signi¢cantly reduced 10 nM insulin-stimulated [3H]2-
DOG uptake and 1 WM TPA-stimulated [3H]2-DOG uptake, re-
spectively. Insulin- or TPA-induced percent change (with or
without C2-ceramide pretreatment) was expressed as the
mean þ S.E.M. *P6 0.05 or **P6 0.01 vs. insulin-stimulated
(without C2-ceramide pretreatment) value. #P6 0.05 vs. TPA-
stimulated (without C2-ceramide pretreatment) value. P was de-
termined by Fisher’s PLSD test. The results are an average of
3^6 determinations and representative for two di¡erent experi-
ments.
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7-fold increase in [3H]2-DOG uptake (694 þ 59%),
and 1 WM TPA stimulation for 30 min provoked a
3.4-fold increase (343 þ 41%), when compared with
the control (100%). Pretreatment with 10, 30 WM
C2-ceramide for 60 min signi¢cantly reduced 10 nM
insulin-stimulated [3H]2-DOG uptake to 4.3- and
3.1-fold increases over the control (100%), respec-
tively (Fig. 2B). Similarly, 1 WM TPA-stimulated
Fig. 3. E¡ect of TNF-K pretreatment on autophosphorylation of IR L-subunit, tyrosine phosphorylation of IRS-1 and PI3K activity.
Rat adipocytes were incubated with or without 0.1^10 nM TNF-K for 60 min, and then stimulated with 10 nM insulin for 10 min.
Adipocytes were lysed and immunoprecipitated with antibodies against the IR L-subunit, IRS-1 or PY. (A) Autophosphorylation of
IR L-subunit. Insulin-stimulated autophosphorylation of IR L-subunit increased to 251 þ 29% (lane 2). Pretreatment with 10 nM TNF-
K for 60 min signi¢cantly suppressed insulin-stimulated autophosphorylation of IR L-subunit (105 þ 29%, lane 4), when compared
with lane 2. The results are the mean þ S.E.M. from three independent experiments. The double asterisks indicate P6 0.01 (Fisher’s
PLSD test). The results shown are representative for three separate experiments. (B) Tyrosine phosphorylation of IRS-1. Insulin-stimu-
lated tyrosine phosphorylation of IRS-1 increased to 175 þ 39% (lane 5). Pretreatment with 0.1^10 nM TNF-K for 60 min signi¢cantly
suppressed insulin-stimulated phosphorylation of IRS-1 (lanes 6^8), when compared with lane 5. The results are mean þ S.E.M. from
three independent experiments. The double asterisks indicate P6 0.01 (Fisher’s PLSD test). The results shown are representative for
three separate experiments. (C) PI3K activity. PI3K was incubated with [Q-32P]ATP and phosphatidylinositol for 10 min. The samples
were separated on a TLC plate and visualized by autoradiography. Non-radioactive phosphatidylinositol 4-phosphate was chromato-
graphed on the same plate as the standard. Insulin-stimulated PI3K activity increased to 299 þ 17% (lane 5), when compared with the
control (lane 1). After pretreatment with 0.1^10 nM TNF-K for 60 min, insulin-stimulated PI3K activity was signi¢cantly reduced
(lanes 6^8), when compared with lane 5. All data were expressed as a percentage of the respective control values. The results are the
mean þ S.E.M. from three independent experiments. The single asterisk indicates P6 0.05 and double asterisks indicate P6 0.01 (Fish-
er’s PLSD test). The results shown are representative for three separate experiments. All data (A, B, C) were analyzed with a laser
densitometer.
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[3H]2-DOG uptake after 10, 30 WM C2-ceramide pre-
treatment for 60 min was signi¢cantly reduced to 2.2-
and 2.0-fold increases over the control (100%), re-
spectively (Fig. 2B).
3.3. E¡ect of TNF-K pretreatment on tyrosine
phosphorylation of IR L-subunit, IRS-1 and PI3K
activity during insulin stimulation
After determination of protein content, equal
amounts of protein were immunoprecipitated at
4‡C with antibody against IR L-subunit or IRS-1,
and then immunoblotted with anti-PY antibody.
Fig. 3 shows tyrosine phosphorylation of proteins
at 95 kDa IR L-subunit (Fig. 3A) and at 180 kDa
IRS-1 (Fig. 3B), respectively. In the absence of any
prior treatment with TNF-K, 10 nM insulin stimula-
tion for 10 min provoked a 2.5-fold increase in in-
sulin-stimulated autophosphorylation of IR L-sub-
unit (251 þ 29%) (Fig. 3A, lane 2), when compared
with the control (100%) (Fig. 3A, lane 1). In a pre-
treatment with 10 nM TNF-K for 60 min, 10 nM
insulin-stimulated autophosphorylation of IR L-sub-
unit was extensively suppressed (Fig. 3A, lane 4),
when compared with lane 2 (without TNF-K pre-
treatment).
In the absence of any pretreatment with TNF-K,
10 nM insulin stimulation for 10 min provoked a
1.75-fold increase in tyrosine phosphorylation of
IRS-1 (175 þ 39%) (Fig. 3B, lane 5), when compared
with the control (100%) (Fig. 3B, lane 1). Pretreat-
ment with 0.1, 1, 10 nM TNF-K, respectively, for
60 min also signi¢cantly reduced 10 nM insulin-
stimulated tyrosine phosphorylation of IRS-1 to
0.91-, 0.94- and 0.4-fold increases over the control
(100%), respectively (Fig. 3B, lanes 6^8). These re-
ductions in tyrosine phosphorylation of IRS-1 were
signi¢cant when compared with lane 5 (without
TNF-K pretreatment).
In the absence of any pretreatment with TNF-K
Fig. 4. E¡ect of 10 nM TNF-K pretreatment for 60 min on insulin- or TPA-stimulated immunoreactivity of membrane-associated
PKCL and j. Rat adipocytes were incubated with or without 10 nM TNF-K for 60 min, followed by treatment with 10 nM insulin or
1 WM TPA for 10 and 20 min. Western blot analysis was performed as described in Section 2. (A) E¡ect of 10 nM TNF-K pretreat-
ment for 60 min on insulin- or TPA-induced immunoreactivity of membrane-associated PKCL. Membrane-associated PKCL immuno-
reactivities were stimulated by 1 WM TPA and 10 nM insulin for 10 and 20 min (lanes 2, 3, 7 and 8). Pretreatment with 10 nM TNF-
K for 60 min signi¢cantly decreased insulin- and TPA-induced immunoreactivity of membrane-associated PKCL (lanes 5, 6, 9 and 10),
when compared with each control (lanes 2, 3, 7 and 8). Insulin- or TPA-induced percent change (with or without TNF-K pretreat-
ment) was expressed as the mean þ S.E.M. **P6 0.01 vs. TPA-stimulated (without TNF-K pretreatment) values. #P6 0.05 or
##P6 0.01 vs. insulin-stimulated (without TNF-K pretreatment) value. P was determined by Fisher’s PLSD test. The results are repre-
sentative for four di¡erent experiments. (B) E¡ect of 10 nM TNF-K pretreatment for 60 min on insulin-induced immunoreactivity of
membrane-associated PKCj. Membrane-associated PKCj immunoreactivities were stimulated by 10 nM insulin for 10 and 20 min
(lanes 2 and 3). Pretreatment with 10 nM TNF-K for 60 min signi¢cantly decreased insulin-induced immunoreactivity of membrane-as-
sociated PKCj (lanes 5 and 6), when compared with lanes 2 and 3. Insulin-induced percent change (with or without TNF-K pretreat-
ment) was expressed as the mean þ S.E.M. **P6 0.01 vs. insulin-stimulated (without TNF-K pretreatment) values. P was determined
by Fisher’s PLSD test. The results are representative for three di¡erent experiments. All (A, B) data were analyzed with a laser densi-
tometer.
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for 60 min, 10 nM insulin-induced PI3K activity sig-
ni¢cantly increased (299 þ 17%) (Fig. 3C, lane 5),
when compared with the control (100%) (Fig. 2C,
lane 1). In contrast, pretreatment with 0.1, 1, 10
nM TNF-K, respectively, for 60 min also signi¢cantly
reduced 10 nM insulin-stimulated PI3K activity to
2.2-, 2.4- and 2.1-fold increases, respectively (Fig.
3C, lanes 6^8), when compared with the control
(100%) (Fig. 3C, lane 1). These reductions in PI3K
activity were signi¢cant when compared with lane 5
(without TNF-K pretreatment).
3.4. E¡ect of TNF-K pretreatment on insulin- or
TPA-stimulated translocation of PKCL and j
In the absence of any prior treatment with TNF-K,
10 nM insulin- or 1 WM TPA-induced PKCL in
membrane fractions increased after both 10 min
and 20 min of stimulation (TPA 10 min:
506 þ 65%; TPA 20 min: 525 þ 100%; insulin
10 min: 328 þ 11%; and insulin 20 min: 451 þ 28%,
respectively) (Fig. 4A, lanes 2, 3, 7 and 8), when
compared with lane 1 (control: 100%). However, fol-
lowing pretreatment of 10 nM TNF-K for 60 min, a
signi¢cant reduction of insulin- and TPA-induced
PKCL in membrane fractions was observed (TPA
10 min: 210 þ 38%; TPA 20 min: 201 þ 25%; insulin
10 min: 190 þ 70%; and insulin 20 min: 239 þ 60%,
respectively) (Fig. 4A, lanes 5, 6, 9 and 10).
In addition, in the absence of any prior treatment
with TNF-K, 10 nM insulin-induced PKCj in mem-
brane fractions increased after both 10 min and
20 min of stimulation (insulin 10 min: 224 þ 25%;
and insulin 20 min: 262 þ 15%, respectively) (Fig.
4B, lanes 2 and 3), when compared with lane 1 (con-
trol: 100%). However, pretreatment with 10 nM
TNF-K for 60 min resulted in a signi¢cant reduction
of insulin-induced membrane-associated PKCj (insu-
lin 10 min: 73 þ 10%; and insulin 20 min: 84 þ 10%,
respectively) (Fig. 4B, lanes 5 and 6), when compared
with each control (Fig. 4B, lanes 2 and 3). Thus, it
appears that pretreatment of 10 nM TNF-K for
Fig. 5. Only TNF-K-stimulated translocation of cytosolic and membrane-associated PKCL. Rat adipocytes were treated with 10 nM
TNF-K for 10 and 30 min. Western blot analysis was performed as described in Section 2. (A) Cytosolic PKCL immunoreactivity. Cy-
tosolic PKCL immunoreactivity increased after stimulation of only 10 nM TNF-K. Treatment with only 10 nM TNF-K for 30 min sig-
ni¢cantly increased PKCL immunoreactivity to 162 þ 17%, when compared with lane 1 (100%). The results are the mean þ S.E.M.
from four independent experiments. The single asterisk indicates P6 0.05 (Fisher’s PLSD test). The results shown are representative
for four separate experiments. (B) Membrane-associated PKCL immunoreactivity. Membrane-associated PKCL immunoreactivity de-
creased after stimulation of only 10 nM TNF-K. Treatment with only 10 nM TNF-K for 30 min signi¢cantly decreased PKCL immu-
noreactivity to 61 þ 10%, when compared with lane 1 (100%). The results are the mean þ S.E.M. from four independent experiments.
The single asterisk indicates P6 0.05 (Fisher’s PLSD test). The results shown are representative for four separate experiments. All
data (A, B) were analyzed with a laser densitometer.
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60 min inhibits 10 nM insulin-induced activation of
membrane-associated PKCL and PKCj.
3.5. E¡ect of TNF-K treatment on the translocation of
PKCL
To determine whether PKCL is a¡ected by 10 nM
TNF-K, we studied only TNF-K-induced alterations
of cytosolic and membrane-associated PKCL in a
time-dependent manner (Fig. 5A,B). Cytosolic
PKCL levels following 10 nM TNF-K exposure for
10 min and 30 min increased to 132 þ 12% and
162 þ 17%, respectively (Fig. 5A, lanes 2 and 3),
when compared with the control (100%) (Fig. 5A,
lane 1). In contrast, membrane-associated PKCL lev-
els decreased to 89 þ 7% (10 min) and 61 þ 10%
(30 min), respectively (Fig. 5B, lanes 2 and 3) from
the control level (100%) (Fig. 5B, lane 1).
4. Discussion
In this paper, we have attempted to examine the
correlation between PKC and TNF-K-induced insu-
lin resistance in rat adipocytes. It has been reported
that insulin mediates IR tyrosine kinase-IRS-1-PI3K
pathway and increases diacylglycerol (DG) produc-
tion by stimulating the synthesis of phosphatidic acid
de novo and the hydrolysis of phosphatidylcholine
and a glycan derivative of phosphatidylinositol
[24,25]. On the other hand, PKC (conventional and
novel PKC) is activated by membrane-associated
DG, which causes PKC to translocate from the cy-
tosol to membranes in various cells including the rat
adipocyte [5^7]. We hypothesize that PKC may di-
rectly or indirectly activate and translocate glucose
transporter to the membrane. For example, PKC
causes phosphorylation of the glucose transporter
[26], and TPA, acting alone, increases PI3K activity
[27]. Thus, TPA-induced activation of PKC may pro-
voke glucose uptake through PI3K-GLUT4 activa-
tion and partially mimics insulin in activating glucose
uptake.
In our studies, a major discovery we have made is
that pretreatment with 0.1^100 nM TNF-K sup-
presses TPA-induced [3H]2-DOG uptake as shown
in Fig. 1A. Furthermore, pretreatment with 10 nM
TNF-K results in a decrease of insulin- and TPA-
induced PKCL translocations (Fig. 4A), and 10 nM
TNF-K, by itself, provokes an increase in cytosolic
PKCL and reduces membrane-associated PKCL im-
munoreactivity(s) in a time-dependent manner as
shown in Fig. 5A,B. Although DG and PKCL signal-
ing during glucose uptake has still not been clari¢ed,
we hypothesize that there is a close correlation be-
tween PKCL activation and glucose uptake [2,3,7,8],
and we have collected data demonstrating that a se-
lective conventional PKC inhibitor, Go« 6976 [28,29],
inhibits insulin- and TPA-induced glucose uptake in
rat adipocytes (data not shown). Moreover, Chalfant
et al. have reported that PKCL2 overexpression en-
hances insulin-stimulated [3H]2-DOG uptake in
NIH-3T3 ¢broblasts [30]. Accordingly, these ¢ndings
suggest that insulin resistance may be relevant to the
inhibition of insulin-induced PKCL translocation in
TNF-K pretreated adipocytes (Fig. 4A) and TNF-K-
mediated reversed translocation of PKCL from the
membrane to cytosol (Fig. 5A,B).
On the other hand, it is known that TNF-K causes
early activation of the sphingomyelin cycle and
sphingomyelin hydrolysis which leads to ceramide
production [31] through activation of the 55 kDa
TNF-receptor [32]. Ceramide has been con¢rmed as
a signal mediator of apoptosis which is induced by
TNF-K. It has been reported that ceramide-induced
apoptosis is inhibited by activation of DG- or TPA-
PKC signaling [33]. Moreover, Jones et al. have pre-
viously reported that sphingomyelinase pretreatment
inhibits diacylglycerol analogue (diC8)-induced
PKCK translocation in HEL-37 mouse epidermal
cell lines [34]. Nakamura et al. and Brindley et al.
have previously demonstrated that the translocation
of PKCL from the cytosol to membrane fraction is
prevented during ceramide inhibition in RBL-2H3
rat basophilic leukemia cell lines and HL-60 human
promyelocytic leukemia cell lines, respectively
[35,36]. More recently, ceramide-induced reversed
translocation of PKCN and O isoforms from the
membrane to cytosol in three di¡erent leukemia cell
lines has been suggested [37]. This study has reported
that conventional PKC (K, L2, Q) does not show sig-
ni¢cant changes, but we have demonstrated TNF-K-
induced alteration of PKCL in rat adipocytes. It is
likely that this di¡erence in PKCL change may be
due to the cell species. Hence, we suspect that
TNF-K utilizes the ceramide activation pathway as
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an important second messenger, due to its e¡ect on
PKCL redistribution and subsequent induction of in-
sulin resistance.
We also have examined translocation of PKCj, an
atypical PKC member. Insulin-induced PKCj trans-
location from the cytosol to membrane fractions, as
well as PKCL, is also inhibited after pretreatment
with 10 nM TNF-K for 60 min (Fig. 4B). Recently,
it has been reported that PKCj is located down-
stream of PI3K, and may lead to GLUT4 transloca-
tion [38,39], while, the results of our experiment and
other previous reports have clearly shown that 10 nM
TNF-K suppresses insulin-mediated autophosphoryl-
ation of IR L-subunit, tyrosine phosphorylation of
IRS-1, and PI3K activation (Fig. 3) [18,19,40,41].
Based on these results, the reduction of insulin-in-
duced PKCj after pretreatment with TNF-K (Fig.
4B) may be, in part, a consequence of a TNF-K-
mediated IR tyrosine kinase-IRS-1-PI3K pathway.
The ¢rst question is whether or not ceramide treat-
ment has been shown to activate PKCj [42^44]. If
ceramide activates PKCj which is involved in glu-
cose uptake, the opposite result would hold for a
glucose uptake study in this system. However, treat-
ment with only TNF-K and C2-ceramide have dem-
onstrated no in£uence on [3H]2-DOG uptake in our
study (Fig. 2A). In addition, pretreatment with
10 and 30 WM C2-ceramide for 60 min has resulted
in a reduction in insulin- and TPA-induced [3H]2-
DOG uptake (Fig. 2B). Although we acknowledge
that ceramide activates PKCj, this translocation by
TNF-K and ceramide occurs towards the nucleus of
the cell [42,43]. As Witters et al. point out [26], glu-
cose transporter is one of the substrates for PKC.
Moreover, Exton et al. have stated that phosphati-
dylinositol 3,4,5-trisphosphate (PIP3), which is phos-
phorylated and activated by PI3K from PIP2, produ-
ces a large stimulation of PKCj [45]. Conceivably,
PIP3-mediated PKCj activation may be di¡erent
from ceramide-induced translocation of PKCj to
the nucleus of the cell.
The second question is whether the dose and in-
cubation period of TNF-K in this study are su⁄cient.
Certainly, the level of TNF-K we have used is a high
concentration. In contrast, many investigators use
0.5^100 ng/ml concentrations and 4 h^7 day incuba-
tion periods of TNF-K. However, the native rat adi-
pocyte is too delicate to incubate for a long term.
The reason why we have selected 10 nM TNF-K in
a PKC study is that this concentration of TNF-K
indicates a su⁄cient e¡ect on insulin-induced glucose
uptake, although the pM level of TNF-K can also
cause a signi¢cant change in glucose uptake. As pre-
viously reported [46], treatment with TNF-K for
60 min is enough to produce ceramide. Therefore,
a 60 min incubation period is suitable for the study
of TNF-K contribution to insulin-induced signal
transduction.
In conclusion, PKCL and j activation may be cor-
related with glucose uptake, and TNF-K-induced re-
versed translocation of PKCL from the membrane to
cytosol may be associated with insulin resistance in
addition to decreased tyrosine kinase-IRS-1-PI3K-
PKCj signaling in rat adipocytes.
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